ASLN - ASLAN Pharmaceuticals Limited

NasdaqGM - NasdaqGM Delayed Price. Currency in USD

ASLAN Pharmaceuticals Limited

No. 12-03 UE Square
83 Clemenceau Avenue
Singapore 239920
65 6222 4235

Full-time employees

Key executives

NameTitlePayExercisedYear born
Dr. Carl Alan Jason Morton FirthChairman & CEO536.51kN/A1973
Mr. Kiran AsarpotaVP of Fin.N/AN/A1979
Dr. Mark McHaleChief Operating OfficerN/AN/A1965
Charlie HsuInvestor Relations DirectorN/AN/AN/A
Mr. Ben GoodgerGen. CounselN/AN/A1963
Amounts are as of 31 December 2016, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


ASLAN Pharmaceuticals Limited, through its subsidiaries, operates as a clinical-stage oncology-focused biopharmaceutical company, developing therapeutics for global markets. It targets diseases that are highly prevalent in Asia, and orphan indications in the United States and Europe. The company's product pipeline includes Varlitinib, which is being studied in a global pivotal trial (TreeTopp) for biliary tract cancer, and a Phase 2/3 trial for gastric cancer, as well as in a single-arm pivotal clinical trial in biliary tract cancer in China. It has rights to develop, manufacture, and commercialize varlitnib for all human and animal therapeutic, diagnostic, and prophylactic uses worldwide. The company is also developing ASLAN002, a potent small molecule inhibitor of RON and receptor tyrosine kinases inhibitor for the treatment of gastric and breast cancer; and ASLAN003, a novel DHODH inhibitor, which is in Phase 2 clinical trials to treat acute myeloid leukemia. In addition, it is developing ASLAN004, a monoclonal IL4/IL13 antibody for the treatment of asthma and severe atopic dermatitis. The company has partnerships with Array BioPharma, Bristol-Myers Squibb, Almirall, and CSL. ASLAN Pharmaceuticals Limited was founded in 2010 and is headquartered in Singapore.

Corporate governance

ASLAN Pharmaceuticals Limited’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.